Výsledky vyhledávání - "Yukinobu Takeshita"

Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)

Autor: Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Yukinobu Takeshita, Katsuji Hattori, Koji Ohmoto, Miki Aihara, Keisuke Nagano, Yoshimasa Isakari, Miho Yamamoto, Yoshitaka Yamamura

Publikováno v: Folia Pharmacologica Japonica. 157:254-260

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::181b1af62301b8c4e2d3d00d0265f3f3
https://doi.org/10.1254/fpj.22006

Zobrazit plný text záznamu

Akademický článek

Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD). (English)

Autor: Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Yukinobu Takeshita, Katsuji Hattori, Koji Ohmoto, Miki Aihara, Keisuke Nagano, Yoshimasa Isakar, Miho Yamamoto, Yoshitaka Yamamura

Publikováno v: Folia Pharmacologica Japonica; 2022, Vol. 157 Issue 4, p254-260, 7p

Zobrazit plný text záznamu

Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)

Autor: Yukinobu Takeshita, Katsuji Hattori, Keisuke Nagano, Yoshitaka Yamamura, Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Miki Aihara, Koji Ohmoto

Publikováno v: Proceedings for Annual Meeting of The Japanese Pharmacological Society. 94:1-S11

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ae1d2e78f57d45a9ccfa03d8c6add5f
https://doi.org/10.1254/jpssuppl.94.0_1-s11-3

Zobrazit plný text záznamu